BEVACIZUMAB-CAPECITABINE (BEV-CAP) AFTER INITIAL 1ST-LINE BEVACIZUMAB-DOCETAXEL (BEV-DOC) IN PATIENTS (PTS) WITH HER2-NEGATIVE METASTATIC BREAST CANCER (MBC): SAFETY ANALYSIS OF THE IMELDA TRIAL

被引：0

作者：

Gligorov, J. ^{[1
]}

Alba-Conejo, E. ^{[2
]}

Bines, J. ^{[3
]}

Cortes, P. A. ^{[4
]}

Doval, D. C. ^{[5
]}

Jiang, Z. ^{[6
]}

Freudensprung, U. ^{[7
]}

Mustacchi, G. ^{[8
]}

机构：

[1] Tenon Hosp, APHP, CancerEst, Paris, France

[2] Hosp Univ Virgen Victoria, Malaga, Spain

[3] Inst Nacl Canc, Rio De Janeiro, Brazil

[4] Hosp Sta Maria HSM CHLN, Ctr Hosp Lisboa Norte, Lisbon, Portugal

[5] Rajiv Gandhi Canc Inst & Res Ctr, New Delhi, India

[6] Acad Mil Med Sci, Affiliated Hosp, Dept Breast Canc, Beijing, Peoples R China

[7] F Hoffmann La Roche Ltd, Global Med Affairs Biometr, Basel, Switzerland

[8] Univ Trieste, Ctr Oncol ASS1 Triestina, Trieste, Italy

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：128 / 128

页数：1